Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABSI Stock Forecast 2026-2027
$11.10
Current Price
$1.88B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ABSI Price Targets
+53.2%
To High Target of $17.00
+17.1%
To Median Target of $13.00
-36.9%
To Low Target of $7.00
ABSI Price Momentum
-4.5%
1 Week Change
+62.5%
1 Month Change
+292.2%
1 Year Change
+218.1%
Year-to-Date Change
-7.9%
From 52W High of $12.06
+395.5%
From 52W Low of $2.24
📊 TOP ANALYST CALLS
Did ABSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Absci Corp is one of their latest high-conviction picks.
Latest ABSI Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ABSI has a bullish consensus with a median price target of $13.00 (ranging from $7.00 to $17.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $11.10, the median forecast implies a 17.1% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Srikripa Devarakonda at Truist Securities, projecting a 53.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABSI Analyst Ratings
10
Buy
1
Hold
0
Sell
ABSI Price Target Range
Low
$7.00
Average
$13.00
High
$17.00
Current: $11.10
Latest ABSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 2, 2026 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $17.00 |
| Jun 25, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $16.00 |
| Jun 24, 2026 | Needham | Buy | Reiterates | $N/A | |
| Jun 24, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jun 15, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jun 4, 2026 | Leerink Partners | Outperform | Initiates | $N/A | |
| May 28, 2026 | BTIG | Buy | Initiates | $N/A | |
| May 8, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Mar 30, 2026 | Needham | Buy | Reiterates | $N/A | |
| Mar 25, 2026 | Needham | Buy | Reiterates | $N/A | |
| Mar 18, 2026 | Needham | Buy | Reiterates | $N/A | |
| Dec 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 12, 2025 | Needham | Buy | Reiterates | $N/A | |
| Nov 13, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 2, 2025 | JP Morgan | Overweight | Initiates | $N/A | |
| Aug 18, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Aug 13, 2025 | Needham | Buy | Maintains | $N/A | |
| Jul 28, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| May 14, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 16, 2025 | Keybanc | Overweight | Maintains | $N/A |
Absci Corporation (ABSI) Competitors
The following stocks are similar to Absci Corp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Absci Corporation (ABSI) Financial Data
Absci Corporation has a market capitalization of $1.88B with a P/E ratio of -13.7x. The company generates $1.84M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -81.8% quarter-over-quarter, while maintaining an operating margin of -14,347.0% and return on equity of -63.9%.
Valuation Metrics
Market Cap
$1.88B
Enterprise Value
$1.68B
P/E Ratio
-13.7x
PEG Ratio
1.4x
Price/Sales
1,045.4x
Growth & Margins
Revenue Growth (YoY)
-81.8%
Gross Margin
N/A
Operating Margin
-14,347.0%
Net Margin
0.0%
EPS Growth
-81.8%
Financial Health
Cash/Price Ratio
+7.3%
Current Ratio
6.6x
Debt/Equity
2.6x
ROE
-63.9%
ROA
-37.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Absci Corporation (ABSI) Business Model
About Absci Corporation
What They Do
Develops AI-driven biologic drugs.
Business Model
The company utilizes a data-first drug creation platform that combines AI models with wet lab technologies to identify, optimize, and produce therapeutic proteins and antibodies. By streamlining the discovery and development processes, Absci generates revenue through partnerships with pharmaceutical and biotechnology companies for the development of AI-designed therapeutics.
Additional Information
Founded in 2011 and based in Vancouver, Washington, Absci is positioned at the intersection of biotechnology and artificial intelligence, focusing on advancing novel drug targets across various disease areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
140
CEO
Mr. Sean McClain
Country
United States
IPO Year
N/A
Website
www.absci.comAbsci Corporation (ABSI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jul 02, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Absci Corporation (ABSI) is being evaluated as a potential top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
The inquiry into Absci Corporation's potential as a momentum stock signals interest in its performance trends, which could influence investor sentiment and stock price movements.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ABSCI Corp (ABSI) experienced a rise in share price with above-average trading volume, but earnings estimate revisions indicate potential weakness ahead.
Why It Matters
ABSCI's recent share price surge on high volume indicates increased interest, but stagnant earnings estimates may signal potential future weakness, prompting caution among investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Absci's stock rose 36% following positive interim Phase I data for ABS-201, indicating good tolerance and potential for infrequent dosing in hair loss treatment.
Why It Matters
Absci's stock surge indicates strong investor confidence in ABS-201's potential, suggesting future revenue growth and market opportunity in hair loss treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AbbVie, Eli Lilly, and Johnson & Johnson shares are poised to reach all-time highs, indicating a renewed investor interest in the biopharmaceutical sector.
Why It Matters
Rising shares of AbbVie, Eli Lilly, and Johnson & Johnson indicate strong investor confidence in the biopharmaceutical sector, potentially signaling growth opportunities and market recovery.
Source: Market Watch
Market Sentiment:
Positive
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
15 days ago
Quick Summary
Absci Corporation (NASDAQ:ABSI) shares rose following positive interim Phase 1 results for its ABS-201 antibody and the announcement of a $100 million stock offering to fund further development.
Why It Matters
Absci Corporation's positive Phase 1 results indicate potential for its drug, boosting investor confidence, while the $100 million offering suggests commitment to further development and growth.
Source: Benzinga
Market Sentiment:
Positive
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
15 days ago
Quick Summary
Eli Lilly & Company and several investment firms, including Adage and BVF Partners, have collectively invested $100 million in Absci.
Why It Matters
The $100 million investment in Absci by major firms signals strong confidence in its technology and potential, likely influencing market perception and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ABSI Stock
What is Absci Corporation's (ABSI) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Absci Corporation (ABSI) has a median price target of $13.00. The highest price target is $17.00 and the lowest is $7.00.
Is ABSI stock a good investment in 2027?
According to current analyst ratings, ABSI has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABSI stock?
Wall Street analysts predict ABSI stock could reach $13.00 in the next 12 months. This represents a 17.1% increase from the current price of $11.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Absci Corporation's business model?
The company utilizes a data-first drug creation platform that combines AI models with wet lab technologies to identify, optimize, and produce therapeutic proteins and antibodies. By streamlining the discovery and development processes, Absci generates revenue through partnerships with pharmaceutical and biotechnology companies for the development of AI-designed therapeutics.
What is the highest forecasted price for ABSI Absci Corporation?
The highest price target for ABSI is $17.00 from Srikripa Devarakonda at Truist Securities, which represents a 53.2% increase from the current price of $11.10.
What is the lowest forecasted price for ABSI Absci Corporation?
The lowest price target for ABSI is $7.00 from at , which represents a -36.9% decrease from the current price of $11.10.
What is the overall ABSI consensus from analysts for Absci Corporation?
The overall analyst consensus for ABSI is bullish. Out of 3 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are ABSI stock price projections?
Stock price projections, including those for Absci Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 2:40 PM UTC